News
Luminary Therapeutics Announces FDA Clearance of IND for LMY-920, a Novel BAFF CAR T-Cell Therapy to Treat Systemic Lupus Erythematosus (SLE). MINNEAPOLIS, MN, UNITED STATES, December 20, 2023 ...
Its primary goal is to determine the maximum tolerated dose and recommended dose of BAFF CAR T-cells for a Phase II trial. Secondary objectives include establishing the toxicity profile, objective ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback